Our Company 2017-07-21T10:32:44+00:00

Board

Chris Indermaur

Chairman

Mr Indermaur has over 30 years of experience in large Australian companies in Engineering, Business Development and Commercial roles. He previously held the role of General Manager of Strategy and Development at Alinta Ltd. Chris holds a Bachelor of Engineering (Mechanical) and a Graduate Diploma of Engineering (Chemical) from the West Australian Institute of Technology (now Curtin University).

Chris also holds a Bachelor of Laws and a Master of Laws from the Queensland University of Technology and a Graduate Diploma in Legal Practice from the Australian National University.

Chris is currently Chairman of Poseidon Nickel Limited, a Non-Executive Director of Aerison Pty Ltd and was previously a Non-Executive Director of the Prime Health Group prior to its sale to Sonic Health Care.

Jack G. Cosentino

CEO/Managing Director

Jack has over 20 years of medical Technology experience as CEO and senior management including Medtronic and most recently Impedimed.

Michael Phelps

Non-Executive Director

Michael Phelps is an American former competitive swimmer and the most decorated Olympian of all time, with a total of 28 medals.

Since retiring from competitive swimming in 2016, Phelps has actively sought to raise awareness around mental health. Prior to his appointment to Medibio’s Board of Directors, Mr. Phelps worked with its team of world-class doctors and medical experts to explore ways in which Medibio’s technology could help address the challenges associated with the identification and treatment of various mental health issues. Mr. Phelps used Medibio’s technology to analyze his own personal datasets and experienced firsthand how it is uniquely positioned to address the challenges associated with mental health diagnosis. “I am honored to accept this appointment because I have personally experienced Medibio’s technology and believe it can help make a profound impact in diagnosing mental health and empowering people to seek the help and support they may need,” said Phelps. “In sports, there is so much focus on the physical aspects of performance, and athletes are analyzed from head to toe. But for many athletes, mental health has not been a topic of focus, and the data analysis aspect of it has been missing up until now. I personally suffered from mental health challenges from my teenage years on, and only fairly recently—after reaching a point of desperation—did I acquire the understanding, treatment, and support I needed, which has truly changed my life. For me, self-awareness, from a mental health standpoint, is empowerment. But I’ve seen firsthand—in sports and beyond—how difficult it is for people to understand, discuss, and confront stress, anxiety, and mental health concerns, all of which can seem like an insurmountable barrier to getting the help and support that is needed. I feel that the ease and objectivity with which Medibio’s technology can accurately help to diagnose mental health will make a profound difference in people’s lives. I want to help others who are dealing with these challenges and make the process for them to take action easier and more understandable.”

Andrew Maxwell

Non-Executive Director

Medical device expert. Commercialised a research project emanating from the Florey Institute of Neuroscience and Mental Health and created a global medical device company.

For 10 years, Andrew led the global growth of Global Kinetics Corporation Ltd (GKC) as Managing Director and Chief Executive Officer. The GKC team commercialised a research project emanating from the Florey Institute of Neuroscience and Mental Health and created a global company with a market leading product for the remote measurement and reporting of the movement disorder symptoms of Parkinson s disease – the Parkinson’s KinetiGraph (PKG).

Franklyn G Prendergast

Non-Executive Director

Franklyn G. Prendergast, M.D., Ph.D. was the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, to its Physician Advisory Board.

Dr Prendergast is the former Chair of the Department of Biochemistry and Molecular Biology and the former director for research at Mayo Clinic from 1989-1992. From 1989-1996, he was a member of the Board of Governors for Mayo Clinic, Rochester. From 1999-2007 inclusive, he was member of Mayo Clinic’s Executive Committee, the senior most internal governance committee for the entire Mayo system. He served on Mayo Clinic’s Board of Trustees continuously between 1992-2009. He was recognized as a Mayo Distinguished Investigator in 1988 and is the director emeritus, Mayo Clinic Cancer Center (1995-2006) and director emeritus for the Mayo Clinic Center for Individualized Medicine (2008-2012). Dr. Prendergast retired from Mayo Clinic in December of 2014.

Dr Prendergast has been a member of the Eli Lilly Company Board of Directors since 1995. He served extensively for the National Institutes of Health (NIH) on numerous study section review groups; as a charter member of the Board of Advisors for the Division of Research Grants, now the Center for Scientific Review; the National Advisory General Medical Sciences Council; the Board of Scientific Advisors of the National Cancer Institute. He held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast also has served in numerous other advisory roles for the NIH. He was a member of the board of directors of the Translational Genomics Research Institute and the Infectious Disease Research Institute (IDRI).

Dr Prendergast’s reputation and experience within US healthcare, especially clinical research.

“I am looking forward to beginning my relationship with Medibio Limited. I am thrilled they are bringing an objective, evidence based test, to the field of mental illness, where none has existed before. This is a ground-breaking area and I am excited to be involved.”

Kris Knaur

Non-Executive Director

A key shareholder of the Company. A consultant to Medibio in the due diligence process, and provides corporate and strategic advice.

Kris will focus corporate matters such as the Board and Senior Management composition and structure, Capital structure, and the ongoing funding requirements for commercialisation of the company’s CHR technology for the diagnosis of Depression and other Mental Health conditions.

Kris has a Bachelor of Science (Honours). Mr Knauer also has over 15 years’ experience in finance and corporate advisory services.

Mr Knauer is an experienced CEO of ASX listed companies and had a previous role as CEO in a group owning GP Centers and Radiology practices. He has previously been the Chairman of Esperance Minerals Limited (ASX: ESM) and former Managing Director of  Citadel Resource Group Limited (ASX: CGG).

Peter Carlisle

Alternate to Michael Phelps

Mr. Peter Carlisle serves as Managing Director of Olympics & Action Sports at Octagon Worldwide, Inc. and Octagon, Inc. Mr. Carlisle oversees contract negotiations, athlete endorsements and licensing and merchandising opportunities.

Mr. Peter Carlisle serves as Managing Director of Olympics & Action Sports at Octagon Worldwide, Inc. and Octagon, Inc. Mr. Carlisle oversees contract negotiations, athlete endorsements and licensing and merchandising opportunities. He has also develops content-driven programs for athletes that are re-defining the term “athlete marketing.” He has more than 15 years of experience in the industry, he has received numerous awards and recognitions, including being named to SportsBusiness Journal’s “Forty Under 40” Hall of Fame, its 20 most influential people in action sports and its 20 most influential sports agents. Sporting News named him to its Power 100 list, and Mr. Carlisle was named one of the best lawyers in America in sports law, including earning the Sports Law Lawyer of the Year in 2012.

Adam Darkins

Non-Executive Director

Adam is internationally recognized for his achievements in building virtual care networks and Telehealth.  His background includes accreditation as a neurosurgeon, leading the U.S. Department of Veterans Affairs Telehealth Program, and as an executive at Medtronic Inc.